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Abstract The activity of the dopamine transporter is an
important mechanism for the maintenance of normal dopami-
nergic homeostasis by rapidly removing dopamine from the
synaptic cleft. In kidney-derived COS-7, COS-1 and HEK-293
but not in other mammalian cell lines (CHO, Y1, Ltk3), we have
characterized a putative functional dopamine transporter dis-
playing a high affinity (KmV250 nM) and a low capacity (V0.1
pmol/105 cells/min) for [3H]dopamine uptake. Uptake displayed
a pharmacological profile clearly indicative of the neuronal
dopamine transporter. Estimated Ki values of numerous sub-
strates and inhibitors for the COS-dopamine transporter and the
cloned human neuronal transporter (human dopamine transpor-
ter) correlate well with the exception of a few notable
compounds, including the endogenous neurotransmitter dopa-
mine, the dopamine transporter inhibitor GBR 12,909 and the
dopaminergic agonist apomorphine. As with native neuronal and
cloned dopamine transporters, the uptake velocity was sodium-
sensitive and reduced by phorbol ester pre-treatment. Two
mRNA species of 3.8 and 4.0 kb in COS-7 cells were revealed
by Northern blot analysis similar in size to that seen in native
neuronal tissue. A reverse-transcribed PCR analysis confirmed
the existence of a processed dopamine transporter. However, no
immunoreactive proteins of expected dopamine transporter
molecular size or [3H]WIN 35,428 binding activity were
detected. A partial cDNA of V1.3 kb, isolated from a COS-1
cDNA library and encoding transmembrane domains 1^6,
displayed a deduced amino acid sequence homology of V96%
to the human dopamine transporter. Taken together, the data
suggest the existence of a non-neuronal endogenous high affinity
dopamine uptake system sharing strong functional and molecular
homology to that of the cloned neuronal dopamine transporter.
z 1999 Federation of European Biochemical Societies.
1. Introduction
The neuronal dopamine transporter (DAT), strategically
localized to presynaptic areas in distal dendritic and axonal
processes of nigrostriatal neurons [1,2], regulates synaptic
dopamine (DA) concentrations by the sodium-dependent re-
uptake of DA, thereby terminating the dopaminergic input to
pre-/post-synaptic DA receptors. Blockade of the neuronal
DA transporter by cocaine, methylphenidate and other psy-
chostimulants increases the extracellular DA that is available
to act upon multiple pre- and post-synaptic receptors, eliciting
psychomotor behavioral events. In DAT knockout mice, a
behavioral phenotype is characterized by spontaneous hyper-
locomotion and absence of any locomotor stimulating e¡ect
by psychostimulant drugs [3] due to the persistent duration of
extracellular synaptic DA [4]. In addition, cocaine and am-
phetamine are ine¡ective on the DA release in these mice
indicating that DAT is a primary target for these drugs,
although some recent work has challenged the notion that
DAT is an obligatory target for the abuse liability of these
compounds [5,6].
The neuronal DA transporter has been cloned and belongs
to the family of 12 transmembrane (TM) domain Na/Cl3-
dependent transporters (see [7^9]). While direct evidence for
the existence of multiple DATs has not been reported, heter-
ogeneity of the DA transporter is suggested by several obser-
vations (reviewed in [9,10]). It is not yet clear whether the
observed pharmacological functional heterogeneity is a result
of di¡erential post-translational modi¢cations of a single DA
transporter [11] or due to the existence of multiple molecular
species or multiconformational states of the transporter
[12,13].
A dopaminergic uptake/transport mechanism is also ex-
pressed in the periphery. The presence of the DA transporter
has been demonstrated in the pancreas [14] and in isolated
parietal cells [15] by immunohistochemistry, while a transport
system for L-dopa and DA is documented in kidney [16^18].
Although the characteristics of the kidney DA transport site
are not concordant with the recognized pharmacology of the
neuronal DAT [16,17], a dopaminergic system within the kid-
ney is strongly supported by the presence of both D1-like and
D2-like DA receptors whose functionality appears to be im-
perative for normal £uid homeostasis (see [19,20]). Peripheral
DA, produced in proximal tubules from circulating L-dopa,
can result in a renal vasodilatation and natriuresis via stim-
ulation of DA D1-like receptors and blockade of a peripheral
DA transport mechanism may, in part, account for cocaine-
induced lethality that can be reduced by speci¢c D1-like re-
ceptor antagonists [21,22].
To begin to assess the molecular nature of peripheral DA
transport mechanisms, we report here the existence of a slow
acting, high a⁄nity DA transporter characterized in cell lines
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originally derived from the kidney (COS-7, COS-1 and HEK-
293) that can be di¡erentiated from the cloned neuronal DAT
on the basis of its expressed pharmacological pro¢le and
mRNA processing.
2. Materials and methods
2.1. [3H]DA uptake
Measurement of DA uptake was performed on intact COS-7, COS-
1 or HEK-293 cells (V2U105 cells/well) plated in 24 well plates and
grown in Dulbecco’s modi¢ed Eagles serum containing 10% fetal bo-
vine serum. COS-7, COS-1, HEK-293 and Ltk3 cells were all ob-
tained from ATTC (Rockville, MD, USA). Brie£y, con£uent cells
were washed with 0.5 ml bu¡er (5 mM Tris, 7.5 mM HEPES,
120 mM NaCl, 5.4 mM KCl, 1.2 mM CaCl2, 1.2 mM MgSO4,
1 mM ascorbic acid, 5 mM glucose, pH 7.1). [3H]DA uptake was
initiated by the addition of the indicated concentrations of dopami-
nergic agents (10311^1034 M) and 10 nM (¢nal concentration) of
[3H]DA (41.4^53.2 Ci/mmol, NEN/Dupont) and incubated in dupli-
cate for 90 min at room temperature. Assays were terminated by
rinsing twice with 0.5 ml bu¡er and solubilization of the cells with
1% SDS (0.5 ml/well) for 15 min at room temperature. Incorporated
radioactivity was measured by liquid scintillation spectrometry in a
Beckman LS 6000SC scintillation counter. Non-speci¢c [3H]DA up-
take was de¢ned in the presence of 10 WM mazindol and was typically
less than 10% of the total. Estimated Km and Vmax values for [3H]DA
uptake and Ki values were analyzed using the non-linear least squares
curve ¢tting program KALEIDAGRAPH (Abelbeck Software).
2.2. Screening of a COS-1 VZAP cDNA library
Since the pharmacological pro¢le of the endogenous DAT from
COS-7 cells appeared to match the pro¢le from COS-1 cells as did
a Southern genomic DNA blot, a COS-1 VZAP cDNA library from
Stratagene was used to clone this endogenous transporter. Brie£y,
duplicate nylon ¢lters (NEN/Dupont) containing a total of
V5U105 clones were screened under the conditions described [9]
with an K32P-labelled nick-translated full-length EcoRI 2 kb hDAT
fragment (1U106 cpm/ml), washed twice in 2USSC, 1% SDS for
15 min 60‡C and once in 1USSC, 1% SDS for 5 min at 60‡C.
Upon plaque puri¢cation of hybridizing clones, in vivo excision and
rescue of the pBluescript SK3 plasmids containing the inserts, South-
ern blot analysis and sequencing, three weakly hybridizing clones were
found to encode the creatine transporter while the fourth more in-
tensely hybridizing clone, an EcoRI 1.3 kb fragment, contained a
sequence homologous to the cloned DAT. Both strands of this clone
were sequenced using the Sanger dideoxy chain termination method
with 7-deaza-dGTP and Sequenase (USB) with either speci¢c internal
primers (Biotechnology Service Centre HSC, Toronto, Ont., Canada)
or T7/T3 primers.
2.3. Northern blot analysis
Total RNA from COS-7 cells and Y1 (2.5U107 cells) was isolated
using TRISOLV (Biotecx) according to the manufacturer’s directions.
Approximately 30 Wg of total RNA was run on a denaturing glyoxal/
DMSO gel, transferred to a nylon membrane (Zeta-probe, Bio-Rad)
and hybridized overnight at 42‡C with 2.5U106 cpm of 32P-labelled
full-length hDAT as described previously [9]. The blot was washed
once at room temperature for 15 min in 2USSC, 1% SDS, once at
65‡C for 15 min in 2USSC, 1% SDS, once at 65‡C for 15 in 1USSC,
1% SDS and once at 65‡C for 15 min in 0.5USSC, 1% SDS.
2.4. Reverse-transcribed (RT)-PCR analysis from COS-1 RNA
Since the clone from the library was prematurely truncated after
TM6, 3P-RACE was performed using V1 Wg total RNA to determine
if the clone was a library artefact. Samples were treated with DNase
for 15 min at room temperature prior to ¢rst strand cDNA synthesis
with 25 pmol of the adapter primer containing an oligo dT sequence
and 200 U Superscript reverse transcriptase (Gibco BRL). The single-
stranded cDNA was then subjected to 30 cycles of PCR ampli¢cation
(denature: 94‡C, 1 min; anneal: 60‡C, 1.5 min; extension: 72‡C,
1.5 min) with 2 U Taq DNA polymerase (Gibco BRL) and 0.5 Wg
of a 5P internal primer (5P-GATTCACTGCAACAACTCCTG-3P) and
a 3P primer created from the sequence 3P to the putative stop after
TM6 (5P-CTCCCTCACTGTCACTTCTGT-3P), transferred to a ny-
lon membrane and probed with a Q-32P end-labelled oligonucleotide
created from the sequence around TM 4 (5P-CAGAGGCTGAAGTA-
GAGCAGCACGATG-3P). The blot was washed once at room tem-
perature for 15 min in 2USSC, 1% SDS and once at 42‡C for 15 min
in 1USSC, 1% SDS. Two hybridizing bands (V670 bp and 540 bp)
revealed on the autoradiograph were subcloned into pBluescript SK3
and sequenced. No bands were evident in the DNase controls.
2.5. Construction and expression of hDAT half mutants
TM 1^6 and TM 7^12 half mutants of hDAT were constructed by
PCR and subcloned into the expression vector pCD-PS. For the TM
1^6 hDAT mutant, PCR primers corresponding to the region 5P to the
start codon (5P primer: 5P-CAGCCCCAACTGCTCGGATGCC-
CATCCTGGTG-3P) and a PCR primer constructed from the loop
before TM7 and incorporating a stop codon (3P primer: 5P-GTCG-
AATTCTTACCTGTAGCAGTTGTTGGT-3P) were used. For the
TM 7^12 mutant, the 5P primer before TM7 was constructed with
an initiation methionine with a predicted Kozak sequence (Kozak,
1986) while the 3P primer was constructed after the stop codon (5P
primer: 5P-GGTACCGCCGCCACCATGGACGCGATTGTCACC-
ACC-3P, 3P primer: 5P- TCTGTCCACCAGCTCA-3P). Approximately
200 ng of hDAT cesium-puri¢ed DNA was subjected to 30 cycles of
PCR ampli¢cation (denature: 94‡C, 1 min; anneal: 60‡C, 1.5 min;
extension: 72‡C, 1.5 min) with 2 U Taq DNA polymerase (Gibco
BRL) and 0.5 Wg of the appropriate primers. Each half mutant was
transfected in COS-7 cells by electroporation ([9]) or in Ltk3 by
DEAE-dextran ([23]) and assayed for [3H]DA after 10 min and
90 min to determine the functionality of the half mutant clones.
All other methods, including immunoblot analyses [24] and
[3H]CFT binding [9], were performed essentially as described.
3. Results and discussion
An uptake system for DA in the periphery, as suggested by
some studies [14^16], would serve as a potential mechanism
for regulating local DA concentrations, preventing accumula-
tion within the general circulation. Using a kidney-derived cell
line (COS-7) commonly used for transient expression func-
tional studies of G protein-coupled receptors and the cloned
neuronal DA transporter, we have characterized the pharma-
cological and molecular properties of a putative endogenous
DA transporter with characteristics cognate to native neuro-
nal DATs. As illustrated in Fig. 1A, the time course for
[3H]DA uptake in hDAT-transfected versus mock or untrans-
fected cells was disparate with the endogenous COS-DAT
di¡ering with respect to initial levels of [3H]DA uptake. Com-
parison of the time course for [3H]DA uptake indicated that
the cloned hDAT when expressed in COS-7 cells and the
endogenous COS-DAT di¡ered by more than 5-fold with
hDAT being linear for up to 15 min, whereas the COS-
DAT uptake was linear for up to 100 min. In contrast, other
cell lines (CHO, YI, Ltk3) did not show any detectable levels
of endogenous [3H]DA uptake, while the total [3H]DA uptake
for Sf9 cells was only V18% of that observed for COS-7 cells
(data not shown).
As depicted in Fig. 1B, [3H]DA uptake measured in mock
or untransfected COS-7 cells exhibited a high a⁄nity with an
expressed Ki of V250 nM. In addition, saturation analysis
indicated that COS-DAT displayed two a⁄nity states for
DA transport as determined by Eadie-Hofstee transformation.
One site represented a high a⁄nity uptake component with an
estimated Km of 130 þ 15 nM and a low translocation velocity
as indexed by an estimated Vmax of 0.12 þ 0.01 pmol/105 cells/
min. The other site consisted of a low a⁄nity, high capacity
component with an estimated Km of 8.3 þ 0.9 WM and a Vmax
of 0.64 þ 0.2 pmol/105 cells/min (Fig. 1B). Signi¢cantly, the
observed high a⁄nity Km for [3H]DA uptake is similar to
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the Km value obtained from native synaptosomal preparations
(50^280 nM) rather than that obtained for the cloned DAT
(V1^5 WM) either expressed transiently or stably in a number
of neuronal and non-neuronal cell lines (see [9,10]). The
cloned human DAT, however, when expressed in Sf9 cells
displayed an apparent a⁄nity (KmV260 þ 60 nM) that corre-
sponded to the Km from striatal synaptosomes [10] and that
reported here. Similarly, carboxyl-terminal tail truncations/
substitutions of hDAT expressed in COS-7 cells also exhibited
an estimated Km of V300 nM [24]. The presence of two dis-
tinct a⁄nity components for the DA uptake, while not ob-
served with full-length hDAT expressed in mammalian or Sf9
cells [9,10], was, however, clearly evident in carboxyl-terminal
tail-truncated hDATs expressed in COS-7 cells with estimated
Km values of 210 nM and 18.9 WM [24]. This suggests perhaps
that DAT sequence-speci¢c motifs particularly within the car-
boxyl-terminus in conjunction with the local cellular micro-
environment may account for the observed di¡erences in Km
values. Interestingly, high a⁄nity [3H]DA uptake was also
observed in two other kidney-derived cell lines, COS-1 and
HEK 293, with a total uptake of 67% and 43%, respectively,
compared to COS-7 cells. Each displayed an estimated Km
value for DA at the high a⁄nity component similar to that
for COS-7 cells (130 þ 15 nM and 280 þ 30 nM, respectively).
In these cell lines, the DA uptake was sodium-sensitive as
indicated by a V80% reduction in total uptake by replace-
ment of NaCl with LiCl (data not shown).
As illustrated in Fig. 2A, [3H]DA uptake was inhibited by
dopaminergic compounds in a concentration-dependent, ster-
Fig. 1. Characterization of [3H]DA uptake by the endogenous COS-
DAT. (A) Comparison of the time course of [3H]DA uptake for
COS-DAT versus hDAT. Data are plotted as the amount of
[3H]DA uptake measured at the time points indicated. Non-speci¢c
binding was de¢ned in the presence of 10 WM mazindol. (B) Repre-
sentative saturation isotherm for [3H]DA uptake. COS-7 cells
(V2.5U105) were incubated with 10 nM [3H]DA and increasing
concentrations of unlabelled DA for 90 min at room temperature as
described in Section 2. Non-speci¢c binding was de¢ned in the pres-
ence of 10 WM mazindol. Inset: Eadie-Hofstee transformation of
saturation data. Data are representative of at least two independent
experiments, conducted in duplicate and which varied by less than
15%.
Fig. 2. Pharmacological pro¢le of the endogenous COS-DAT. (A)
Representative curves of the inhibition of [3H]DA uptake in COS-7
cells. Cells (V2U105/well) were incubated with 10 nM [3H]DA and
the indicated concentration of competing agents (10311^1034 M)
and assayed for [3H]DA uptake activity as described in Section 2.
Estimated Ki values are listed in Table 1. Data are representative of
at least two or three independent experiments, each conducted in
duplicate and which varied by less than 15%. (B) Correlation plot
of estimated Ki values for the [3H]DA uptake for COS-DAT com-
pared to hDAT. Estimated Ki values for inhibition of [3H]DA up-
take by a series of DAT uptake inhibitors and substrates for hDAT
were taken from ([9,24]). A line of identity is shown.
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eoselective and uniphasic manner (as determined by Hill co-
e⁄cients close to unity). Estimated Ki values for several dop-
aminergic substrates and inhibitor compounds (listed in Table
1) for [3H]DA uptake in COS-7 cells correlate extremely well
with Ki values obtained from the cloned hDAT [9,24] or with
native neuronal DATs. As depicted in Fig. 2B, only a few
compounds, the exceptions noted, di¡erentiated the cognate
COS-DAT from the expressed cloned hDAT, namely DA and
apomorphine which exhibited a V10-fold higher a⁄nity for
COS-DAT. In contrast, GBR 12,909 displayed a between
5- and 10-fold lower a⁄nity for COS-DAT than expected.
The observed di¡erences in the pharmacological pro¢les along
with the detected di¡erences in the initial rates of DA uptake
between cloned and cognate DATs in COS-7 cells were used
to con¢rm the observed heterogeneity in pharmacology of the
two transporters. Thus, when hDAT was transfected into
COS-7 cells and assayed for [3H]DA uptake after 10 min,
the standard time period for transfected DAT uptake assays,
the Ki value for apomorphine was approximately 1920 þ 280
nM. This is in contrast to the Ki value of 354 þ 87 nM for the
endogenous DAT or the somewhat intermediate Ki of
715 þ 98 nM for hDAT-transfected COS-7 cells assayed after
a 90 min incubation period (data not shown). Thus, the en-
dogenous COS-DAT under the appropriate experimental con-
ditions can functionally contribute or modulate the pharma-
cological characteristics of the cloned hDAT. DA uptake was
not, however, inhibited by L-dopa (up to 100 WM) or by the
NE uptake blocker desipramine (10 WM), nor could the pres-
ence of a high a⁄nity [3H]NE uptake system in COS-7 cells be
detected. The inability to observe [3H]NE uptake (10 nM)
may be related to the rather low density of high a⁄nity
COS-DATs and the reduced translocation velocity exhibited
by DAT for non-preferred substrates [25]. In line with this
observation is the fact that no speci¢c [3H]WIN 35,428
(CFT) binding was observed in control or mock-transfected
whole cell assays or prepared membranes [9,24] despite the
ability of this compound to inhibit the DA uptake with a
high a⁄nity. It appears therefore that the sites mediating
the appropriate expression of substrate or inhibitor a⁄nities
at the ligand binding domain of COS-DAT-like molecules, at
least as indexed by [3H]WIN 35,428 (CFT), are distinct from
those conferring the recognition of these compounds for the
DA translocation processes. Similar observations have been
made with the cloned human DAT (e.g. [24] and references
therein).
Similar to other Na/Cl3-dependent transporters [26^28],
the cognate COS-DAT appeared to be regulated by second
messenger activation of protein kinase C. Thus, after pretreat-
ment with 1 WM PMA, a protein kinase C activator, for 30
min, a signi¢cant drop (V80%) in Vmax for DA occurred with
no large change in apparent Km (V700 þ 150 nM). No such a
reduction in Vmax was procured after pretreatment with 10
WM forskolin (104% of control total [3H]DA uptake) suggest-
ing that protein kinase A does not modulate the activity of
this transporter, similar to the lack of e¡ect of 8-Br-cAMP on
DA uptake into striatal synaptosomes [29,30] or on DAT
phosphorylation [31]. In both native striatal synaptosomes
and heterologous expression systems, the DA uptake (Vmax)
is decreased when treated with PMA with no apparent change
in Km [24,30,32^34]. The exact nature of the decrease in the
apparent DA translocation velocity after protein kinase C
activation is unknown but may be due to the rapid sequestra-
tion of the DAT protein from the cell surface as demonstrated
by immuno£uorescent confocal microscopy [10].
The presence of a functional COS-7 DA transporter with
characteristics quite similar to native neuronal or cloned
DATs predicted the presence of a DAT mRNA transcript in
these cells. As illustrated in Fig. 3A, Northern blot analysis of
Fig. 3. Characterization of endogenous COS-DAT-like transporter.
(A) Northern blot analysis of COS-7 and Y1 RNA. Total RNA
(V30 Wg) isolated from COS-7 and Y1 cells using TRISOLV was
denatured, electrophoresed on a 1% agarose DMSO/glyoxal gel,
transferred to a nylon membrane and probed with a 32P-labelled
full-length hDAT fragment. The sizes of the hybridizing bands are
indicated to the left. (B) Southern blot of RT-PCR-ampli¢ed prod-
ucts from COS-1. Samples of COS-1 total RNA were subjected to
reverse transcriptase (RT) using oligo (dT) and then to PCR with
two additional COS-1 DAT-speci¢c oligonucleotide primers (see
Section 2). Ampli¢ed products from the RT-PCR analysis and from
PCR analysis o¡ the cDNA clone and COS-1 VZAP II library were
Southern-blotted and probed with a COS-1 DAT-speci¢c 32P-la-
belled oligonucleotide primer internal to the PCR products. Sizes of
hybridizing bands (bp) are indicated. (C) Southern blot of RT-PCR-
ampli¢ed products from COS-7. COS-7 total RNA was subjected to
reverse transcriptase using oligo (dT) followed by PCR ampli¢cation
with the same two COS-1 DAT-speci¢c oligonucleotide primers.
Ampli¢ed products were Southern-blotted and probed with a COS-1
DAT-speci¢c 32P-labelled oligonucleotide primer internal to the
PCR products. The same two hybridizing bands (V670 bp and
V540 bp) are evident in COS-7 cells. DNase control with no re-
verse transcriptase (RT) is located to the right. Sizes of hybridizing
bands (bp) are shown.
Table 1
Ki values (nM) for inhibition of [3H]DA by COS-DAT
Compound COS-DAT (nM) COS-DAT/hDAT
Amfonelic acid 2.2 0.73
(+)-Diclofensine 3.0 0.38
WIN 35,428 4.9 0.38
Lu 19,005 5.7 0.46
Mazindol 8.0 1.0
Methylphenidate 10.3 0.48
Cocaine 65 0.76
GBR 12,909 159 11.3
Buproprion 171 0.33
DA 250 0.15
Apomorphine 354 0.18
Amphetamine 416 3.59
(3)-Diclofensine 605 1.00
6,7-ADTN 843 1.80
SCH-23390 2 800 0.54
NPA 7 500 0.75
SKF-38393 7 600 2.62
Norepinephrine 9 500 1.11
Serotonin s 50 000 s 1
Ki values for inhibition of [3H]DA uptake are listed in order of po-
tency. Data represent the means of at least 2^4 independent experi-
ments, each conducted in duplicate and which varied by less than
15%. Ratios were determined using the Ki values from [9,34] for
COS-7 cells transiently expressing hDAT.
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total RNA extracted from COS-7 cells and probed with full-
length 32P-labelled hDAT indicated the presence of two lightly
hybridizing bands of V3.8 and 4.0 kb. This is in agreement
with the estimated transcript size of the rat (V3.7 kb, [35])
and the human neuronal DA transporter (V4.2^4.5 kb,
[36,37]). As expected, no discernible hybridizing bands could
be detected in Y1 cells, as these cells do not display any high
a⁄nity uptake of [3H]DA (data not shown). The presence of
multiple COS-DAT mRNA species may be indicative of splice
variants or di¡erent transcription start or polyadenylation
sites [38]. To ascertain whether DAT-like protein are present
and maturely processed in these cells, membranes of untrans-
fected COS-7 and COS-7 cells expressing hDAT were sub-
jected to Western blotting with polyclonal antibodies to
hDAT [1]. However, no speci¢c immunoreactive bands were
present in untransfected COS-7 cells. Moreover, no immuno-
reactive labelling of untransfected COS-7 cells could be visual-
ized by confocal microscopy [10].
In an attempt to determine the molecular nature and de-
duced amino acid composition of the processed COS-DAT, a
commercially prepared COS-1 cDNA library was screened
under medium stringency conditions with full-length hDAT.
A COS-1 cell line library was chosen since COS-1 displayed
endogenous DAT-like functional activity and Southern blot-
ting of EcoRI, SacI, PstI, XhoI and HindIII restriction-di-
gested genomic COS-1 and COS-7 DNA with a 32P-labelled
hDAT yielded identical hybridization patterns (data not
shown). Four hybridizing clones were isolated, three of which
produced a weak hybridization signal and upon sequence
analysis were determined to encode the creatine transporter,
cloned previously from kidney [39]. The fourth clone (EcoRI
1.3 kb fragment) which hybridized intensely with hDAT was
found by sequence analysis to contain a deduced amino acid
sequence1 virtually identical (96%) to hDAT. However, quite
surprisingly, while the clone contained a poly A sequence at
the 3P-end preceded by V500 bp 3P-UTR, the clone appeared
to be prematurely truncated as indexed by the presence of a
stop codon following TM6 at exon/intron boundary 7. No
clones containing TM 7^12 were obtained from this library
as revealed by re-screening the library with a fragment encod-
ing TM8 to the carboxyl-terminus of hDAT. RT-PCR analy-
sis was therefore performed on COS-1 and COS-7 RNA using
an internal 5P-speci¢c oligonucleotide primer within the
encoding sequence and a 3P oligonucleotide primer con-
structed from the isolated 3P untranslated cDNA sequence.
As illustrated in Fig. 3B and C, two ampli¢ed cDNA products
of apparent sizes, V670 bp and V540 bp, were revealed.
Upon sequence analysis, the 670 bp fragment yielded the ex-
pected sequence with a stop codon after exon 7 (encoding
TM6) identical in position to the putative stop codon seen
with the cDNA clone isolated from the library, while the
540 bp product revealed that exon 6 (encoding TM5) was
missing. Taken together, these results indicate that the COS-
1 cDNA DAT clone, at least at the 3P-end of the clone, is not
simply a product of aberrant library construction and suggests
that under appropriate conditions and in a cell-speci¢c man-
ner, preferential processing of ‘truncated’ forms of the DAT
are evident in both COS-1 and COS-7 cells. Similar to other
members of this transporter family [40^43], the DA transport-
er gene contains several exons separated by intronic sequences
[37,44], suggesting the possibility of alternative splicing. The
human serotonin transporter appears to be alternatively
spliced within the 5P non-encoding regulatory region [43] while
alternative mRNA splicing of the norepinephrine transporter
(NET) gives rise to proteins with variant carboxyl-termini that
di¡er with respect to their functional expression [42,45]. Alter-
natively, the inability to acquire a full-length clone may be
due to the low abundance of this transporter mRNA in these
kidney-derived cell lines.
Since we were unable to ¢nd a full-length clone from the
COS-1 library or obtain evidence for a corresponding trun-
cated version of COS-DAT protein via immunodetection, we
assessed whether truncated DA transporters can confer the
uptake characteristics observed in these cells. Recent studies
have suggested that truncated GLUT1 glucose transporters
(TM 1^6 and TM 7^12) can re-aggregate to form functional
proteins [46]. Two hDAT mutants were generated by PCR,
one encoding sequence beginning with the initiation methio-
nine and terminating within the third intracellular loop (Arg-
344) at the identical position to that seen with the isolated
COS-1 cDNA clone and the other hDAT ‘half’ mutant encod-
ing a Kozak sequence with an initiation methionine sequence
that has been shown to naturally occur in one reported clone
of the human hDAT sequence [47] followed by the remaining
carboxyl-terminal half (TM7-CT end) of the protein. [3H]DA
uptake was assessed in either COS-7 or Ltk3 cells following
transient expression of either mutant alone or after co-expres-
sion to determine if the two halves of the transporter could re-
assemble to form a functional transporter. The half mutants,
either expressed individually or concurrently, could not dem-
onstrate any speci¢c [3H]DA uptake above that which occurs
endogenously in these cells when assayed at either 10 or 90
min, thereby indicating that these two half mutants were not
functional (data not shown).
In summary, we report the characterization of an endoge-
nous DA transporter in several kidney-derived cell lines
(COS-7, COS-1 and HEK-293) and a partial cDNA clone
from COS-1 cells that shares functional, pharmacological
and molecular characteristics of the cloned neuronal DAT.
The presence of a functional DAT-like activity in these cells,
although a low capacity, con¢rms the reported presence of
DAT proteins within the periphery [14,15] and suggests that
peripherically re-uptake of DA may serve as an additional
mechanism for regulating DA concentrations. The isolation
of a prematurely truncated DAT-like molecule indicates that
the DA transporter may be subjected to alternative proces-
sing depending on the cell type. However, functional analyses
of truncated hDAT mutants suggest that these truncated
forms do not mediate DA uptake. Possibly, these forms
may require additional ions, co-transporters or transport-
adapter proteins to mediate uptake or, alternatively, may
function only as releasers. In any event, we have con¢rmed
the existence of a peripheral DAT, as suggested by immuno-
histochemical studies. The further localization of DAT within
the periphery may indicate a more widespread role for the
DAT function.
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